A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Cardiovascular Outcomes Following Treatment With Alogliptin in Addition to Standard of Care in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

drug protocol number
SYR-322_402
drug sponsor
Takeda
drug study
Alogliptin
drug trial site
N\A
drug status
Rejected
drug phase